Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Boston Scientific finalizes Bolt Medical acquisition as FDA clears company’s IVL technology
Boston Scientific hopes to officially launch its new IVL system in the first half of 2026.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Bringing state-of-the-art healthcare to Florida heart patients
Naples Comprehensive Health is building up what it hopes will be a nationally recognized cardiology program. Robert Cubeddu, MD, and Dee Dee Wang, MD, spoke with Cardiovascular Business about the journey so far.

Cardiva Medical® Announces FDA Approval of VASCADE® Vascular Closure System for Use in Femoral Vein Closure

Santa Clara, Calif. — April 5, 2018 — Cardiva Medical®, an innovator in the field of vascular closure, today announced the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication of the VASCADE® Vascular Closure System. Already approved for use in arterial closure, VASCADE is now FDA approved for use in 5-7F femoral venous closures as well.

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

DUBLIN — April 9, 2018 — Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension).

Cardiologist argues for combination therapy for stroke, heart attack—but is anyone listening?

Victor Gurewich, MD, has spent more than two decades trying to spread the word about what he sees as an effective, lifesaving treatment approach to heart attack and stroke. At 88 years old, the cardiologist is hoping to breakthrough soon—and a new clinical trial in Europe could help.

Genetic testing to inform antiplatelet choice reduces adverse events post-PCI

A genetic test to inform decisions about what antiplatelet to use following percutaneous coronary intervention (PCI) significantly reduced the number of major cardiovascular or cerebrovascular events in a single-center study published in Circulation: Genomic and Precision Medicine.

LGB adults have poor cardiovascular health compared to heterosexual counterparts

Lesbian, gay and bisexual adults are likely to have poor cardiovascular health compared to heterosexual counterparts, according to findings presented March 20 at the American Heart Association’s Epidemiology and Lifestyle conference in New Orleans.

Higher mortality rates in women after PCI driven by noncardiac causes

The higher rates of all-cause mortality after percutaneous coronary intervention (PCI) observed in women can be attributed to noncardiac factors, suggests a single-center study published in Circulation: Cardiovascular Interventions.

Teaming Up to Treat Pulmonary Emboli: Clotbusters Illustrates Potential of Coordinated Response Programs

At one hospital, an aggressive treatment PE treatment program has dramatically reduced mortality.

Interventional Cardiology

Boston Scientific finalizes Bolt Medical acquisition as FDA clears company’s IVL technology

Key takeaways from ACC.25: Advances in cardiovascular science

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Bringing state-of-the-art healthcare to Florida heart patients